Pharmaceutical expenditure in Sweden

被引:12
|
作者
Henriksson, F
Hjortsberg, C
Rehnberg, C
机构
[1] Stockholm Sch Econ, Ctr Hlth Econ, S-11383 Stockholm, Sweden
[2] Swedish Inst Hlth Econ, S-22002 Lund, Sweden
关键词
age; disease categories; market segments; pharmaceutical expenditures; policy implications; reform;
D O I
10.1016/S0168-8510(99)00016-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Recently, the responsibility for prescribed pharmaceuticals in Sweden was transferred from national level to the regional health authorities (county councils). The purpose was that a closer integration and balance between pharmaceuticals and other factors of production in health care should produce better opportunities for a cost-effective use of the total health care resources. The purpose of this paper is to present a deeper analysis of pharmaceuticals as a production factor in Sweden, mainly during the 1990s, and to discuss the future development and future policy decisions in Sweden. Pharmaceuticals have increased their share of total health care expenditure in Sweden, from about 9% in 1990 to about 14% in 1995. The Swedish pharmaceutical market can be divided into sub-markets, where the prescription sub-market accounts for the greater part of pharmaceutical expenditure. Further, a few disease categories account for a larger fraction of the cost of prescribed pharmaceuticals. The importance of pharmaceuticals as a production factor also differs between different age groups. Several factors are expected to contribute to a future increase in Swedish pharmaceutical expenditure, for instance an ageing population and the rapid introduction of expensive new pharmaceuticals. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:125 / 144
页数:20
相关论文
共 50 条
  • [41] The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure
    Clarke, Philip M.
    MEDICAL JOURNAL OF AUSTRALIA, 2013, 198 (05) : 260 - 260
  • [42] The Effects of Investment and Research Expenditure on Chemical and Pharmaceutical Industries
    Simionescu, Mihaela
    Popescu, Jenica
    Meita, Nela Loredana Caraba
    REVISTA DE CHIMIE, 2019, 70 (08): : 2940 - 2943
  • [43] Cost-sharing and pharmaceutical utilisation and expenditure in Russia
    Street, A
    Jones, A
    Furuta, A
    JOURNAL OF HEALTH ECONOMICS, 1999, 18 (04) : 459 - 472
  • [44] VARIATION IN IRISH GMS PHARMACEUTICAL EXPENDITURE BY ATC CLASSIFICATION
    ConwayLenihan, A.
    Woods, N.
    Ahern, S.
    Moore, S.
    Cronin, J.
    VALUE IN HEALTH, 2016, 19 (03) : A56 - A56
  • [45] Cross-state disparities in pharmaceutical expenditure in the US
    Lopez-Vila, Eduardo Daniel
    Montanes, Antonio
    Simon-Fernandez, Maria Blanca
    APPLIED ECONOMICS, 2025,
  • [46] FORECASTING OUTPATIENT PHARMACEUTICAL EXPENDITURE FOR CANCER TREATMENT IN GERMANY
    Schoch, G. G.
    Blank, S.
    Tamminga, M.
    Steimle, T.
    Stargardt, T.
    VALUE IN HEALTH, 2014, 17 (07) : A621 - A621
  • [47] Pharmaceutical expenditure and therapeutic value of new medicines in Spain
    Darba, J
    PHARMACOECONOMICS, 2003, 21 (16) : 1211 - 1212
  • [48] Age and gender in pharmaceutical expenditure: A tool for risk calculation
    Perramon, AGI
    Luque, DM
    VALUE IN HEALTH, 2005, 8 (06) : A191 - A191
  • [49] Age and gender distribution of pharmaceutical expenditure per inhabitant
    Gilabert-Perramon, A
    Magem-Luque, D
    VALUE IN HEALTH, 2004, 7 (06) : 716 - 717
  • [50] PHARMACEUTICAL EXPENDITURE AND POTENTIAL AVENUES FOR COST CONTAINMENT IN IRELAND
    Heaney, R. M.
    Judge, G.
    Fortescue-Webb, D.
    Coughlan, J. J.
    Barry, M.
    VALUE IN HEALTH, 2009, 12 (07) : A245 - A245